Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
Sep 07 – Sep 14, 2026
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This ad hoc exploratory analysis of the phase 3, double-blind KEYNOTE-826 randomized clinical trial evaluated 5-year efficacy and safety of pembrolizumab plus platinum-based chemotherapy (with or without bevacizumab) versus placebo in 617 patients with previously untreated persistent, recurrent, or metastatic cervical cancer across 151 sites in 19 countries. At a median follow-up of 59.1 months, pembrolizumab plus chemotherapy sustained an overall survival benefit in the PD-L1 CPS ≥1 population (median 28.6 vs 16.5 months; HR 0.62; 95% CI 0.50-0.76) and intention-to-treat population (26.4 vs 16.8 months; HR 0.64; 95% CI 0.53-0.78). Progression-free survival advantage was similarly maintained (median 10.5 vs 8.2 months; HR 0.58; 95% CI 0.48-0.71 in CPS ≥1; 10.4 vs 8.2 months; HR 0.61; 95% CI 0.51-0.74 in ITT). No new safety signals were observed, confirming the durability of benefit and reinforcing pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer.
10.1001/jamaoncol.2026.3547
Aug 31 – Sep 07, 2026
Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial.
FRONT IMMUNOL · Q1 JOURNAL - RANK #32/183
This multicenter, single-arm, phase II trial (ASTRUM-CC01) evaluated serplulimab plus bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer. Forty-eight patients were enrolled and received 4-6 cycles of the combination followed by maintenance therapy. The objective response rate was 75.00% (95% CI, 60.40-86.36), with a median progression-free survival of 21.23 months (95% CI: 14.43-NR) and a 12-month overall survival rate of 83.97% (95% CI: 73.66-95.72). The authors concluded that this regimen demonstrated promising antitumor activity with an acceptable safety profile, supporting further evaluation in phase III trials.
10.3389/fimmu.2026.1923961
Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.
INT J GYNECOL CANCER · Q1 JOURNAL - RANK #8/140
This post hoc analysis of the phase 3, multi-national, open-label, randomized ENGOT-cx12/GOG-3057/innovaTV 301 trial (NCT04697628) evaluated patient-reported outcomes (PROs) in patients with recurrent or metastatic cervical cancer receiving second- or third-line tisotumab vedotin versus investigator’s choice chemotherapy. Patients were randomized 1:1, and PROs were measured using EORTC QLQ-C30, QLQ-CX24, and EQ-5D-5L instruments. Analyses of change from baseline to cycle 13 using mixed models showed health-related quality of life was maintained with no significant between-arm differences, while the proportion with clinically meaningful (≥10-point) improvement was higher for tisotumab vedotin on most subscales. Time to deterioration was slower with tisotumab vedotin for most subscales, notably nausea/vomiting and pain, supporting it as a treatment option.
10.1016/j.ijgc.2026.104947
Aug 17 – Aug 24, 2026
T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors.
J TRANSL MED · Q1 JOURNAL - RANK #24/195
This phase I investigator-initiated trial evaluated the safety, feasibility, and preliminary efficacy of autologous tumor-infiltrating lymphocyte (TIL) therapy in twelve Asian patients with advanced melanoma, cervical, lung, or head and neck cancers who had progressed after standard therapies. Patients received lymphodepletion chemotherapy, TIL infusion, and high-dose IL-2, with tumor assessments per RECIST 1.1. The objective response rate was 33.3% (4/12), including one complete response and three partial responses, with a disease control rate of 75% (9/12). TCR sequencing showed dynamic clonal remodeling in responders, and CRISPR-mediated knockout of ASS1 or CEP20 enhanced TIL antitumor function, suggesting these genes as potential targets to improve TIL therapy.
10.1186/s12967-026-08781-z